Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH

Zydus, a leading innovation-led global lifesciences company,  has announced positive topline results from its completed EVIDENCES-X™ Phase II(b), prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium in patients with Metabolic dysfunction Associated Steatohepatitis (MASH) and fibrosis.